Sanofi Stock: How I Leveraged This Undervalued Dividend Aristocrat (NASDAQ:SNY)
· seekingalpha.com
Sanofi’s vaccines segment had a negative 4.7% YoY growth in Q2’26, being dragged down by flu and COVID-19. Learn why SNY stock is a buy.
Sanofi ( SNY ) has been punished by the market due to multiple pipeline failures recently. That’s very important, indeed, because these pipeline candidates sh...